Vivo Capital’s ArriVent BioPharma AVBP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$54.1M Buy
1,787,104
+105,007
+6% +$3.22M 5.96% 4
2026
Q2
$58.4M Buy
1,682,097
+796,181
+90% +$23.5M 5.34% 4
2026
Q1
$20.4M Buy
+885,916
New +$20M 1.7% 20

Other funds holding AVBP

Vivo Capital's AVBP Position: Q3 2026 in Review

Vivo Capital increased its ArriVent BioPharma (AVBP) stake by 6.2% in Q3 2026, buying an estimated $3.22M and bringing the position to 1,787,104 shares worth $54.1M. The position accounts for 5.96% of the portfolio, ranked #4.

Vivo Capital first reported a position in AVBP in Q1 2026 and has held it in 3 quarters since. The position peaked at $58.4M in Q2 2026. 153 funds tracked by Wall St. Rank hold AVBP as of Q3 2026.

  • Vivo Capital held 1,787,104 shares of ArriVent BioPharma worth $54.1M as of Q3 2026.
  • Vivo Capital bought 105,007 ArriVent BioPharma shares in Q3 2026, an estimated $3.22M.
  • ArriVent BioPharma made up 5.96% of Vivo Capital's portfolio in Q3 2026, its #4 holding.
  • Vivo Capital first reported a position in ArriVent BioPharma in Q1 2026 and has held it in 3 quarters since.
  • Vivo Capital's ArriVent BioPharma position peaked at $58.4M in Q2 2026.
  • 153 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q3 2026.

Based on Vivo Capital's 13F filing for Q3 2026, filed 13 Nov 2026.